Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Press Releases

Keyword Search

October 22, 2020
CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference
MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri , Chairman, CEO, and Co-Founder of Ocugen, will
Additional Formats
PDF Version
October 6, 2020
Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200
Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned MALVERN, Pa., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today
Additional Formats
PDF Version
August 28, 2020
Ocugen to Present at the LD 500 Virtual Investor Conference
MALVERN, Pa., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the LD 500 Virtual Investor Conference on Friday,
Additional Formats
PDF Version
August 14, 2020
Ocugen Provides Business Update and Second Quarter 2020 Financial Results
Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing
Additional Formats
PDF Version
August 10, 2020
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
Additional Formats
PDF Version
Displaying 1 - 10 of 22